Agents and mechanisms of toxic myopathy

Current Opinion in Neurology

Volumn 22, Issue 5, 2009, Pages 506-515

  Kuncl, Ralph W ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Colchicine vacuolar myopathy; Myopathies from edible fungi; SLCO1B1 susceptibility gene; Statin necrotizing myopathy; Zidovudine mitochondrial myopathy

Indexed keywords

7 [4 (4 FLUOROPHENYL) 6 ISOPROPYL 2 [METHYL(1 METHYL 1H 1,2,4 TRIAZOL 5 YL)AMINO] 5 PYRIMIDINYL] 3,5 DIHYDROXY 6 HEPTENOIC ACID; ACETYLSALICYLIC ACID; AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTIN; CIMETIDINE; COLCHICINE; CYCLOSPORIN; DIAZEPAM; DILTIAZEM; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; MACROLIDE; MEVINOLIN; PLACEBO; PRAVASTATIN; PREDNISONE; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG; VERAPAMIL; WARFARIN; XUEZHIKANG; ZIDOVUDINE;

CALCIUM TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DOSE TIME EFFECT RELATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; EDIBLE MUSHROOM; GENETIC SUSCEPTIBILITY; HUMAN; HYPERCHOLESTEROLEMIA; META ANALYSIS; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL MYOPATHY; MUSCLE BIOPSY; MYOSITIS; NONHUMAN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TOXIC MYOPATHY; TOXICOKINETICS;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MONASCUS; MUSCULAR DISEASES;

EID: 70349706034     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32833045a0     Document Type: Review

References (64)

1. Romano GJ, Lehar M, Kuncl RW. Toxic myopathies. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE, editors. Neuromuscular disorders in clinical practice. 1st ed. Boston: Butterworth Heinemann; 2002. pp. 1205-1215 and color plates pp. 44-50.
2. Seib JP, Gillessen T. Iatrogenic and toxic myoapathies. Muscle Nerve 2003; 27:142-156.
3. Walsh RJ, Amato AA. Toxic myopathies. Neurol Clin 2005; 23:397-428.
4. Klopstock T. Drug-induced myopathies. Curr Opin Neurol 2008; 21:590-595.
5. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681-1690.
6. Hennekens CH. Statin-induced myopathy: hypothesis about randomized evidence and clinical impressions. Am J Med 2009; 122:4-5.
7. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97:52C-60C.
8. Gaist D, Rodriguez LAG, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12:565-569.
9. McAdams M, Staffa J, Dal Pan G. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2008; 17:229-239.
10. Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the Adverse Event Reporting System. Am J Cardiol 2006; 97:S32-S43.
11. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28:26-35.
12. Ahmad S, Madsen CS, Stein PD, et al. (3R,5S,E)-7-(4-(4-fluorophenyl)-6- isopropyl-2-(methyl(1-methyl-1H-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5- dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor with reduced myotoxicity potential. J Med Chem 2008; 51:2722-2733.
13. SEARCH Collaborative. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008; 359:789-799.
14. Poels PJE, Gabreëls FJM. Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg 1993; 95:175-192.
15. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106:1024-1028.
16. Westwood FR, Bigley A, Randall K, et al. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 2005; 33:246-257.
17. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic andpharmacokinetic properties of statins. PharmacolTher1999;84: 413-428.
18. Kobayashi M, Chisaki I, Narumi K, et al. Association between risk of myopathy and cholesterol lowering effect: a comparison of all statins. Life Sci 2008; 82:969-975.
19. Sakamoto K, Mikami H, Kimura J. Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres. Br J Pharmacol 2008; 154:1482-1490.
20. Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997; 145:91-98.
21. Vaklavas C, Chatzizisis YS, Ziakas A, et al. Molecular basis of statin-associated myopathy. Atherosclerosis 2009; 202:18-28.
22. Flint OP, Masters BA, Gregg RE, Durham SK. HMG Co-A reductase inhibitorinduced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell cultures. Toxicol Appl Pharmacol 1997; 145:99-110.
23. Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during shortterm simvastatin treatment in humans. Clin Pharmacol Ther 1995; 57:62-66.
24. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77:851-854.
25. Schaars CF, Stalenhoef AFH. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Op Lipidol 2008; 19:553-557.
26. Waclawik AJ, Lindal S, Engel AG. Experimental lovastatin myopathy. J Neuropathol Exp Neurol 1993; 52:542-549.
27. Schaefer WH, Lawrence JW, Loughlin AE, et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal muscle myopathy in rats. Toxicol Appl Pharmacol 2004; 194:10-23.
28. Nakahara K, Kuriyama M, Yoshidome H, et al. Experimental simvastatininduced myopathy in rabbits. J Neurol Sci 1992; 113:114-117.
29. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137:581-585.
30. Liantonio A, Giannuzzi V, Cippone V, et al. Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system. J Pharmacol Exp Ther 2007; 321:626-634.
31. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statinassociated myotoxicity. Curr Op Pharmacol 2008; 8:333-338.
32. Nakamura Y. Pharmacogenomics and drug toxicity. N Engl J Med 2008; 359:856-858.
33. Rodrigues AC, Hirata MH, Hirata RDC. The genetic determinants of atorvastatin response. Curr Opin Mol Ther 2007; 9:545-553.
34. Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008; 20:648-656.
35. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nature Rev Drug Discov 2007; 6:904-916.
36. Omar MA, Wilson JP, Cox RS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35:1096-1107.
37. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80:565-581.
38. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3- methylglutaryl- coenzyme A reductase inhibitors. Clin Pharmacokinet 1996; 31: 348-371.
39. Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc 2000; 40:637-644.
40. Meena AK, Ratnam DV, Chandraiah G, et al. Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure1 in treating hyperlipidemia. Lipids 2008; 43:231-241.
41. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008; 47:463-474.
42. Riggs JE, Schocet SS, Gutmann L, et al. Chronic human colchicine neuropathy and myopathy. Arch Neurol 1986; 43:521-523.
43. Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med 1987; 316:1562-1568.
44. Wallace SL, Singer JZ, Duncan GJ, et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991; 18:264-269.
45. Kuncl RW, Bilak MM, Craig SW, Adams R. Exocytotic 'constipation' is a mechanism of tubulin/lysosomal interactions in colchicine myopathy. Exp Cell Res 2003; 285:196-207.
46. Hsu W-C, Chen W-H, Chang M-T, Chiu H-C. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol 2002; 25:266-268.
47. Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve 2004; 30:799-802.
48. Tateishi T, Soucek P, Caraco Y, et al. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol 1997; 53:111-116.
49. Ucar M, Myorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22:441-457.
50. Schiff D, Drislane FW. Rapid-onset colchicine myoneuropathy. Arthritis Rheum 1992; 35:1535-1536.
51. Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337:508-510.
52. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-422.
53. Kiyomoto BH, Tengan CH, Godinho RO. Effects of short-term zidovudine exposure on mitochondrial DNA content and succinate dehydrogenase activity of rat skeletal muscle cells. J Neurol Sci 2008; 268:33-39.
54. Bedry R, Baudrimont I, Deffieux G, et al. Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med 2001; 345:798-802.
55. Nieminen P, Kirsi M, Mustonen A-M. Suspected myotoxicity of edible wild mushrooms. Exp Biol Med 2006; 231:221-228.
56. Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999; 69:231-236.
57. Prasad GVR, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002; 74:1200-1201.
58. Lu Z, Kou W, Du B, et al., and the Chinese coronary secondary prevention study group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008; 101:1689-1693.
59. Becker DJ, Gordon RY, Morris PB, et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc 2008; 83:758-764.
60. Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol 2008; 66:572-574.
61. Smith DJ, Olive KE. Chinese red rice-induced myopathy. South Med J 2003; 96:1265-1267.
62. Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med 2006; 145:474-475.
63. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245.
64. Tuccori M, Lombardo G, Lapi F, et al. Gabapentin-induced severe myopathy. Ann Pharmacother 2007; 41:1301-1305.